ClinicalTrials.gg
CompletedNCT05432492Updated Mar 4, 2026

A Study of AK112 in Patients With Unresectable Hepatocellular Carcinoma (HCC)

A Phase 2 interventional study of AK112 in Hepatocellular Carcinoma, sponsored by Akeso. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-04.

Sponsored by Akeso · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Carcinoma, Hepatocellular by Akeso — 5 open to participants now, 6 under way, 2 of them phase 3. Carcinoma, Hepatocellular · Akeso.

Enrollment
8th of 10
40 · median 80
Started
2022
with 1 other
Phase 2
6 of 10
2 open now
Registered
5th of 10
by date

Among the 10 studies in Carcinoma, Hepatocellular by Akeso, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 6 in phase 2, and was the 5th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

5 of the 10 studies in Carcinoma, Hepatocellular by Akeso are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Carcinoma, Hepatocellular by Akeso, or all of them as a file.
02

Study summary

Phase II open label, multicenter study to evaluate the efficacy and safety of AK112 (PD-1/VEGF Bispecific) in patients with unresectable hepatocellular carcinoma (HCC).

03

Conditions studied

  • Hepatocellular Carcinoma
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be able and willing to provide written and to comply with all requirements of study participation (including all study procedures).
  • 18 to 75 years old.
  • (ECOG) performance status of 0 or 1.
  • Have a of at least 3 months.
  • BCLC stage B or C, not amenable to curative surgery.
  • Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
  • At least one measurable untreated lesion.
  • class A.
  • Has adequate organ function.
  • All female and male subjects of must agree to use an effective method of , as determined by the Investigator, during and for 120 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • With fibrous lamellar hepatocellular carcinoma, sarcomatoid hepatocellular carcinoma, cholangiocarcinoma components in tumor tissues.
  • History of other than HCC within 5 years, except that basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  • Have a history of hepatic encephalopathy or have a history of liver transplantation.
  • With clinical symptoms requires drainage of pleural effusion, ascites or pericardial effusion.
  • Central nervous system (CNS) or meningeal metastasis.
  • Prior immunotherapy with an , anti-PD-L1, or anti-CTLA-4 antibody (or any other antibody or drug specifically targeting T-cell costimulation or checkpoint pathways).
  • Prior systemic bevacizumab and its analogues treatment.
  • Severe bleeding tendency or coagulation dysfunction; occurred arteriovenous thromboembolic events or bleeding events due to esophageal and/or gastric varices within 6 months before the first administration.
  • Known presence or history of required hormone treatment interstitial lung disease or non-infectious pneumonitis.
  • Has an active disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, or drugs). Replacement therapy (e.g., thyroxine, insulin or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
  • Has undergone major surgery within 30 days prior to the first dose of study treatment.
  • History of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Cohort 1

    Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.

    Drug: AK112

  • Experimental
    Cohort 2

    Subjects receive AK112 on Day 1 of every 3-week cycle (Q3W) until progression.

    Drug: AK112

Interventions

  • DrugAK112

    IV infusion, specified dose on specified days

06

What researchers measure

Primary outcomes

  1. Number of patients with Adverse Events (AEs)

    Time frame: Up to approximately 2 years

  2. Objective Response Rate (ORR) Per RECIST v1.1

    Time frame: Up to approximately 2 years

  3. Objective Response Rate (ORR) Per mRECIST

    Time frame: Up to approximately 2 years

Secondary outcomes

  1. Disease control rate (DCR)

    Time frame: Up to approximately 2 years

  2. Duration of Response (DoR)

    Time frame: Up to approximately 2 years

  3. Time to response (TTR)

    Time frame: Up to approximately 2 years

  4. Progression free survival (PFS)

    Time frame: Up to approximately 2 years

  5. Overall survival (OS)

    Time frame: Up to approximately 2 years

Other outcomes

  1. Percentage of participants who obtain R0 resection

    Time frame: Up to approximately 2 years

  2. Percentage of participants who obtain a major pathologic responses (MPR)

    Time frame: Up to approximately 2 years

  3. Percentage of participants who obtain a pathologic complete response (pCR)

    Time frame: Up to approximately 2 years

07

Study locations

1 site
  • Fujian Provincial Cancer Hospital
    Fuzhou, Fujian, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2022 to primary completion in Apr 2025, 32 months.

Of 80 industry-sponsored phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 50. This study's 32 months is below that.

Counting every sponsor, half of 429 studies reached it within 43 months; a quarter within 30 and three quarters within 71.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 21, 2022
First posted
Jun 27, 2022
StartActual
Aug 3, 2022
Primary completionActual
Apr 30, 2025
CompletionActual
Jun 14, 2025
Last update
Mar 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05432492
Lead sponsor
Akeso
Responsible party
Sponsor
First posted
Jun 27, 2022
Start date
Aug 3, 2022
Primary completion
Apr 30, 2025
Completion
Jun 14, 2025
Last update
Mar 4, 2026

Study contacts

Jingfeng Liu
principal investigator · Fujian Cancer Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion